Details for Patent: 8,168,637

Summary for Patent: 8,168,637

Title:	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
Abstract:	The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s):	Scott D. Edmondson, Dooseop Kim, Malcolm MacCoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US12/694,758
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 8,168,637: Scope, Claim Boundaries, and U.S. Patent Landscape for a Simvastatin Plus “First Compound” Combination for Type 2 Diabetes

Executive summary. US Patent 8,168,637 claims a U.S. drug combination: (i) a pharmaceutical composition containing simvastatin plus a second “first compound” defined only by a formula in the patent, and (ii) a Type 2 diabetes treatment method using the same “first compound” together with simvastatin. The enforceable scope turns on how broadly the formula-defined “first compound” is interpreted (Markush coverage, salt forms, and whether stereochemistry and substitution limits narrow coverage), plus how courts treat claim pairing requirements (simvastatin as a required component for both composition and method claims). The landscape for combination coverage is typically shaped by: whether the “first compound” is itself covered by earlier patents, whether later continuation/divisional claims exist around the same pairing, and whether FDA product labeling and Orange Book listings connect simvastatin drug products to the “first compound” combination claims.

---

What does US Patent 8,168,637 claim, and what is the enforceable scope?

Short answer (claim scope). The patent has two independent claim families that are tightly coupled by a required pairing:

1. A composition claim requiring simvastatin plus a “first compound” of a formula (or a pharmaceutically acceptable salt) plus a carrier.
2. A method-of-treatment claim for Type 2 diabetes requiring administration of the “first compound” plus simvastatin in a therapeutically effective amount.

Claim 1: pharmaceutical composition requiring a defined formula compound + simvastatin + carrier

Claim 1 is structured as a closed combination:

• Element A: “a first compound of the formula: or a pharmaceutically acceptable salt thereof”
• Element B: simvastatin
• Element C: “a pharmaceutically acceptable carrier”

Enforceability hinges on three boundaries.

1. Formula coverage: The claim includes “a first compound of the formula” rather than a named compound. If the formula is implemented as a Markush group, the patentee typically obtains coverage across many substituent options within the defined variables. If the formula uses fixed substituents rather than ranges, the scope narrows to fewer exact chemical structures.
2. Salt coverage: The phrase “or a pharmaceutically acceptable salt thereof” extends coverage beyond the free base (or parent form). The claim still requires that the salt corresponds to the same underlying “first compound.”
3. Carrier permissiveness: “pharmaceutically acceptable carrier” is usually broad and typically covers conventional excipients. This lowers design-around options around formulation excipients.

Claim 2: method of treating Type 2 diabetes with the same paired components

Claim 2 requires:

• Administration to a mammalian patient in need thereof
• A therapeutically effective amount of the “first compound” (formula-defined or pharmaceutically acceptable salt)
• Plus simvastatin

Key enforceable boundary. The claim’s therapeutic intent is Type 2 diabetes. A competitor could seek to avoid infringement by (a) changing the therapeutic use, (b) changing the pairing (remove simvastatin), or (c) changing the “first compound” to one that falls outside the formula definition. However, if the “first compound” plus simvastatin is the same regimen for Type 2 diabetes and is actually used for that purpose, the method claim can be triggered by actual medical practice.

---

How broad are the “first compound” formula claims likely to be?

Short answer. The scope depends on whether the formula is drafted with Markush substituent ranges and whether those ranges are constrained by defined “R” groups, ring systems, stereocenters, and valence constraints.

Markush-style breadth controls design-around

For combination patents of this style, “formula” claims often function as a Markush claim. If so:

• Competitors must determine whether their candidate molecule falls within the defined variable ranges.
• Substituent substitutions outside the allowed variable lists can create a clear non-infringing path.
• Substituent changes that keep the structure within the variable set can still infringe even if the compound is not previously synthesized in the patent.

Stereochemistry and salts can narrow or broaden in practice

• If the formula specifies a stereochemical configuration, epimers/enantiomers may fall outside the claim even if they have similar pharmacology.
• If the claim does not specify stereochemistry, courts sometimes read formula claims to cover all stereoisomers encompassed by the written formula. The patent’s specification and claim construction matter materially for how broadly it is interpreted.

Salt language is usually an “add-on” extension, not a separate compound

The “pharmaceutically acceptable salt thereof” language extends coverage to salts of an in-claim parent compound. It does not create coverage for different underlying structures.

---

What patents most likely affect freedom to operate (FTO) around US 8,168,637?

Short answer. The infringement analysis is only half the job. FTO risk typically comes from earlier patents on:

• the “first compound” itself (active ingredient patents),
• simvastatin combination use (method-of-use patents), and
• formulation or crystalline forms that could block commercialization depending on the competitor’s manufacturing and product strategy.

Landscape segmentation

1. Active ingredient patents for the “first compound”

   • If the “first compound” is a known class (commonly diabetes drugs such as GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, TZDs, etc.), earlier composition-of-matter patents may already be in force for that compound.
   • If the “first compound” is novel, the same patent family may contain the core composition-of-matter claims, and 8,168,637 may sit as a combination extension.

2. Simvastatin use and combinations

   • Simvastatin has longstanding patent history, but combination-method patents may still exist for particular therapeutic uses or particular co-administered agents.

3. Combination formulation and dosing patents

   • Even if the actives are not blocked, product-specific patents (fixed-dose combination tablets, co-crystalline forms, specific dosage regimens) can create barriers.

How 8,168,637 interacts with other patents

In combination patents, overlapping coverage typically arises in two ways:

• A competitor may fall within 8,168,637 because they co-administer simvastatin with a formula-defined compound.
• Even if they avoid 8,168,637 by choosing a non-formula compound, they may still be blocked by patents on that compound’s own composition-of-matter or protected formulation.

---

When does US 8,168,637 expire, and what does that mean for generic or fixed-dose launch timing?

Short answer. Expiration and exclusivity depend on the patent’s priority, prosecution history, and term adjustments. The user-provided content does not include filing/priority dates, issuance date confirmation, maintenance status, or any terminal disclaimers.

Because the prompt includes only claim text and not priority/issue details, any computed expiration date would be speculative. The analysis below states what matters conceptually for launch timing rather than providing an ungrounded date.

Timing for Paragraph IV and generic risks

If the “first compound” is the active ingredient in a competing branded drug or is present in a co-pack:

• A generic entrant might attempt to file a Paragraph IV certification against the listed Orange Book patents for the combination product (if listed).
• Even without Orange Book listing, method-of-use and composition patents can still support infringement suits if there is actual use for the claimed Type 2 diabetes indication.

Fixed-dose versus co-administration

• If a competitor launches a fixed-dose combination, they are more directly aligned with the composition claim’s carrier-containing pharmaceutical composition structure.
• If a competitor uses separate dosage forms that are co-administered, method claims can still be asserted if the regimen is used to treat Type 2 diabetes and includes both components.

---

What would an infringement theory look like for the composition claim (Claim 1)?

Short answer. The patentee’s prima facie case usually requires proving that the accused product is:

• a pharmaceutical composition
• containing simvastatin
• containing a compound that falls within the formula-defined “first compound” (or its salt)
• formulated with pharmaceutically acceptable carrier(s)

Common defenses and how they impact claim elements

• “Not within the formula”: structural non-infringement.
• “No simvastatin”: design-around by substitution.
• “Different salt form”: if salt is not “pharmaceutically acceptable” or does not correspond to the in-claim parent, that can matter.
• Carrier argument: usually weak because carriers are standard excipients.

Claim construction drivers

• Construction of “formula” terms is typically the most contested.
• Construction of “pharmaceutically acceptable” is usually broad, but can still be litigated for edge-case salts.

---

What would an infringement theory look like for the method claim (Claim 2)?

Short answer. The patentee typically relies on showing administration of the two-drug regimen to treat Type 2 diabetes with a therapeutically effective amount.

Evidence used in method-of-use cases

• Labeling, prescribing information, and promotional materials
• Clinical protocols and dosing instructions
• Real-world use patterns and pharmacovigilance records

Design-around options

• Avoid the claimed therapeutic use (hard if off-label is still promoted; easier if products are truly used outside Type 2 diabetes).
• Remove simvastatin from the regimen.
• Use a “first compound” outside the formula scope.

---

How strong is the patent estate for combination coverage like this?

Short answer. US 8,168,637 is strong only to the extent:

• the formula-defined “first compound” is specific enough to remain novel and non-overlapping,
• there are not many earlier disclosures of similar “first compounds” plus simvastatin combinations,
• the claim is construed broadly (Markush breadth) and is not narrowed during prosecution.

The user-provided content does not include prosecution history, file wrapper documents, or related family patents, so strength can’t be scored numerically here without introducing unsupported assessments.

---

Which competitors would be at risk, and what launch scenarios create the highest exposure?

Short answer. Exposure concentrates around parties developing Type 2 diabetes regimens that include simvastatin plus a compound matching the “first compound” formula.

Highest-risk scenarios

1. Fixed-dose combination tablet/capsule containing both actives.
2. Co-pack or kit where both drugs are administered together for Type 2 diabetes under a regimen consistent with “therapeutically effective amount.”
3. Label-directed combination therapy for Type 2 diabetes.

Lower-risk scenarios

• Regimens that use simvastatin but omit the “first compound” or use a compound outside the formula.
• Use in a different indication without Type 2 diabetes treatment targeting (still may be challenged depending on how the claim is enforced in practice).

---

What Orange Book status questions matter for US 8,168,637?

Short answer. Orange Book listings depend on whether there is an approved drug product that contains simvastatin and the formula-defined “first compound” such that the FDA lists this patent for that NDA/ANDA.

The prompt does not include the drug name(s) for the “first compound,” the relevant NDA/ANDA, or the FDA listing status. Without those, it is not possible to state whether US 8,168,637 appears in the Orange Book.

---

Key takeaways

• US 8,168,637 covers a simvastatin + formula-defined compound combination for Type 2 diabetes, in both composition and method-of-treatment claims.
• The most important claim boundary is the formula-defined “first compound” scope, including Markush coverage, stereochemistry, and salt interpretation.
• Design-around primarily occurs by removing simvastatin, using an out-of-formula compound, or avoiding use that is demonstrably for Type 2 diabetes under a therapeutically effective regimen.
• Generic and fixed-dose launch timing depends on priority/expiration data and whether any product is Orange Book-linked to this patent; those details are not present in the provided prompt.

---

FAQs

1. What elements must an accused product contain to infringe Claim 1 of US 8,168,637?
   A pharmaceutical composition containing simvastatin, a formula-defined “first compound” (or its pharmaceutically acceptable salt), and a pharmaceutically acceptable carrier.

2. Can a company avoid Claim 2 by co-administering separate products instead of a fixed-dose combination?
   Yes in some cases, but infringement can still occur if the regimen is used to treat Type 2 diabetes with both required actives.

3. Does changing the salt form avoid infringement of the formula-defined “first compound”?
   It can, if the salt is not within the claim’s “pharmaceutically acceptable” scope or if it corresponds to a non-in-claim parent structure.

4. How does stereochemistry affect the “first compound of the formula” coverage?
   If stereochemistry is specified in the claim construction, off-configuration stereoisomers may fall outside the claim.

5. What is the biggest uncertainty for enforcement of US 8,168,637?
   How broadly the “formula” claim is construed, including variable limits and whether Markush groups cover the competitor’s structure.

---

References

1. U.S. Patent 8,168,637 (claims provided in prompt).

Drugs Protected by US Patent 8,168,637

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,168,637

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1412357		PA2007006	Lithuania
European Patent Office	1412357		SPC/GB07/046	United Kingdom
European Patent Office	1412357		122007000056	Germany
European Patent Office	1412357		CA 2008 00035	Denmark
European Patent Office	1412357		91470	Luxembourg